Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

VYVGART 1.000 MG SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/VYVGART 1.000 MG SOLUCION INYECTABLE

Approved

STANDARD

VYVGART 1.000 MG SOLUCION INYECTABLE

Argenx B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jan 18, 2024
Approval ID: ee1ea14b206637c0
Company: Argenx B.V.
Type: Standard

Approval Details

Approval Id: ee1ea14b206637c0
Drug Cima Aemps Name: VYVGART 1.000 MG SOLUCION INYECTABLE
Register Number: 1221674002
Holder Company Name: Argenx B.V.
Marketing Company Name: Argenx Spain S.L.
Authorization Date: 2024-01-18
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 1000 mg
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Argenx B.V.

Active Ingredients

EFGARTIGIMOD ALFA

1000 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jan 18, 2024

Approval ID

ee1ea14b206637c0

Type

Standard

Back to CIMA-AEMPS Approvals